RhoAgent Designs RNA Drugs Autonomously. The FDA Has No Playbook for What Comes Next.
RhoAgent, an AI "virtual scientist," autonomously designs functional RNA molecules. With RNAi Phase 1-to-3 transition rates at 64.4%, the...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Authority FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Protocol Design Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
RhoAgent, an AI "virtual scientist," autonomously designs functional RNA molecules. With RNAi Phase 1-to-3 transition rates at 64.4%, the...
Clinical trial sites face enrollment challenges: 11% enroll zero patients, while budget delays push FPI dates past target.
APR-1051 showed partial responses in PPP2R1A-mutated uterine cancers in Phase 1 trial data, suggesting potential molecular-driven clinical activity.
FDA's cardiac safety reviewers explain what the insufficient-information statement in a label actually signals, why a post-marketing QTc signal...
Major drugmakers are halting China hospital trials. Acting Commissioner Diamantas, the FDA has no framework to manage the protocol...
Telomir Pharmaceuticals partners with Linical CRO to advance Telomir-Zn TNBC trial, targeting first-patient enrollment in Q1 2027 for advanced...
FDA Provides Pre-IND Feedback on Tvardi's TTI-109, an oral STAT3 inhibitor for inflammatory bowel disease, clearing the path toward...
MICVO demonstrates 39% response rate in recurrent head and neck cancer patients, with 81% one-year overall survival probability in...
AlpE combination shows TB activity comparable to isoniazid in Phase 2a trial, positioning it as potential replacement for isoniazid-resistant...
J&J's $2.2B Ollin buyout pairs with a Blackstone funding deal, and that split ownership of trial money creates site...